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In this research we describe the improvement of the water-solubility of cyclic epitope
mimics based on the HCV E2 glycoprotein by incorporation of suitable polar hinges.
The poor solubility of epitope mimics based on peptide sequences in the envelope
(E2) protein hampered their synthesis and purification and made it very difficult to
prepare the molecular constructs for evaluation of their bioactivity. Since changes in
the amino acid composition are hardly possible in these epitope mimics in order to
increase water-solubility, a polar cyclization hinge may offer a remedy leading to a
significant increase of polarity and therefore water solubility. These polar hinges
were applied in the synthesis of better water-soluble HCV-E2 epitopes. An azide
functionality in the polar hinges allowed attachment of a tetraethylene glycol linker
by Cu-catalyzed azide-alkyne cyclo-addition (CuAAC) for a convenient conjugation to
ELISA plates in order to evaluate the bio-activity of the epitope mimics. The immuno-
assays showed that the use of more polar cyclization hinges still supported anti-HCV
antibody recognition and did not negatively influence their binding. This significantly
increased solubility induced by polar hinges should therefore allow for the molecular
construction and ultimate evaluation of synthetic vaccine molecules.
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1 | INTRODUCTION
The rapidly increasing therapeutic potential of cyclic peptides is due
to multiple favourable molecular attributes.25 These attributes include
the ability to access large and often flat surface areas within protein
binding sites, thereby achieving high-selectivity and binding-affinity.
Furthermore, peptide cyclization improves its proteolytic stability
compared to the linear peptide. Earlier, we have shown that cyclic
peptides therefore might be especially attractive in the molecular con-
struction of epitope mimics.17,29 Moreover, it was recently found that
cyclic peptides were better epitope mimics than the linear, non-
cyclized compounds.17,29 As part of our efforts directed towards syn-
thetic vaccines we have been especially interested in HIV-gp120 and
the HCV-E2.21,29 Presently the focus is on HCV, which is a rapidly
mutating and highly diverse virus. The natural immune response to
this virus often falls short due to various immune evasive strategies
and hypervariable immunogenic decoy domains of the virus that do
not impede its viral efficiency.1,18,19,22 In essence, the immune system
of the host is exhausting itself by targeting ineffective viral epitopes.
Despite enormous efforts, no vaccine is available as yet against
HCV.20 An approach to remedy this might be selection of effective
and conserved epitopes, which could be mimicked by cyclic peptides
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and thereby, circumvent problems with immunogenic decoys and inef-
ficient epitopes.23
Multiple cyclic peptides were considered based on promising neu-
tralizing epitopes located within the CD81 binding site of the HCV E2
glycoprotein. This binding site consists of 4 epitope domains
(Epitopes I, II, III, and IV) to which various antibodies have been gener-
ated and isolated that bind these epitopes individually (continuous) or
as parts of a larger domain (discontinuous).24 Their therapeutic poten-
tial is based on these antibodies being capable of neutralizing HCV
infection by blocking the CD81 binding site of the E2 glycopro-
tein.2,8,26 Epitopes II and IV were found to bind the same class of
HC84 antibodies.8,24 Recently, we have shown that antibody HC84.1
binds our previously developed epitope II mimic without parts of epi-
tope IV.17 Therefore, in this study we have focused on epitopes I, II,
and III.
One of the most attractive cyclization methods, presently avail-
able is based on thioether-formation with cysteine-containing pep-
tides. Electrophilic bromide (for example benzylic-bromide) derivatives
and Michael acceptors (Figure 1), among others, have been applied in
the synthesis of many diverse (bi)cyclic peptides also towards syn-
thetic vaccines.3-5,9-11,14,15,17,27-29 However, depending on the
sequence, the solubility of cyclized peptides onto a benzylic core (i.e.
TBMB) or derivatives thereof can be very poor. Poor water-solubility
may hamper purification of cyclized peptides using reverse phase
chromatography, resulting in very low yields thereby also limiting their
therapeutic potential. In general, poor water-solubility of peptides is
often responsible for a large attrition rate similar to that observed in
the small molecule drug discovery process.6
Several hinges with increasing polarity for cyclization of peptides
have been described in the literature to improve the water solubility
of resulting molecular constructs.3-5,9-12,15,16,27 Examples of such
polar hinges are shown in Figure 1 and include the 2,4,6-1,3,5-
triacryloyl-1,3,5-triazinane (TATA), N,N0,N00-(benzene-1,3,5-triyl)-tris
(2-bromoacetamide) (TBAB) and N,N0,N00-benzene-1,3,5-triyltrisprop-
2-enamide (TAAB) tris (bromomethyl)-s-triazine (TBMT) and 1,10 ,100-
(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone) (TATB) cyclization
hinges.9,12,16 Especially, the latter two, recently developed by us, have
shown to be beneficial for the aqueous solubility of cyclic peptides.16
Recently, Heinis et al. have described a phage display protocol
with respect to high-throughput screening of bicyclic peptides,
thereby opening up a wide range of potential therapeutics.4 Interest-
ingly, they found that different hinge structures (i.e. TBMT, TATA,
TBAB, and TAAB) incorporated into bicyclic peptides resulted in dif-
ferent conformations of the bicyclized peptide.9 Moreover, changing
the cyclization hinge on a promising isolated sequence from the phage
display library could reduce or even completely abolish (binding) activ-
ity.3,9,27 In addition, depending on the used cyclization hinge, different
peptide consensus sequences were isolated from the phage display
library.27 Taken together, this suggested that the core structure of the
cyclization hinges does have a significant impact on the overall struc-
ture of the cyclized peptide.
The main goal of the work reported here focussed on the
improvement of the water-solubility of cyclic epitope mimics based
on the HCV E2 glycoprotein by incorporation of suitable polar hinges.
The poor solubility of the peptide sequences corresponding with
these epitopes hampered the synthesis and purification of the epitope
mimics, and made it very difficult to prepare the molecular construct
for evaluation of their bioactivity. Evidently, possibilities to change
amino acids in these epitope mimics in order to increase water-
solubility are very limited, as their peptide sequences have to resem-
ble the mimicked peptide segments of the epitopes as closely as pos-
sible. Recently, we have addressed the issue of poor solubility of
peptide loops for attachment to our molecular (TAC) scaffolds by
development of polar hinges, which upon incorporation led to a signif-
icant increase of polarity and therefore their water solubility. There-
fore, we wished to apply these polar hinges in the synthesis of better
F IGURE 1 Chemical structures of cyclization
hinges for preparation of bicyclic peptides 1,3,5-tris
(bromomethyl)benzene (TBMB) (A); 1,3,5-triacryloyl-
1,3,5-triazinane (TATA), N,N0 ,N00-(benzene-1,3,5-triyl)-
tris(2-bromoacetamide) (TBAB) and N,N0,N00-benzene-
1,3,5-triyltrisprop-2-enamide (TAAB) described by
Chen et al.9 and Rim et al.12 (B); and 2,4,6-tris
(bromomethyl)-s-triazine (TBMT) and 1,10 ,100-
(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone)
(TATB) described by Van de Langemheen et al.16 (C)
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water-soluble HCV-E2 epitopes. Here, we describe the preparation of
cyclized synthetic peptide sequences onto various cyclization (polar)
hinges, equipped with a functional azide handle.16 In addition, an
alkyne-functionalized linker equipped with a trityl-protected thiol moi-
ety is described that allowed for conjugation of cyclic peptides with
different core structures via by Cu-catalyzed azide-alkyne cyclo-
addition (CuAAC). Upon deprotection of the thiol-moiety, the resulting
epitope mimics were readily conjugated to a maleimide-activated sur-
face and their bio-activity was evaluated by ELISA (Figure 2).
2 | MATERIALS AND METHODS
2.1 | General
All reagents and solvents were used as received. Fmoc-amino
acids were obtained from Activotec (Cambridge, United Kingdom)
and N,N,N0 ,N0-Tetramethyl-O-(6-chloro-1H-benzotriazol-1-yl)uranium
hexafluorophosphate (HCTU) was obtained from Matrix Innovation
(Quebec, Canada). Tentagel S RAM resin (particle size 90 μm, capac-
ity 0.25 mmol.g−1) was obtained from IRIS Biotech (Marktredwitz,
Germany). Methyl tert-butyl ether (MTBE), Hexane (HPLC grade)
and TFA were obtained from Aldrich (Milwaukee, USA). DMF
(Peptide grade) was obtained from VWR (Lutterworth, United King-
dom). Piperidine, DiPEA were obtained from AGTC Bioproducts
(Hessle, United Kingdom) and 1,2-ethanedithiol (EDT) was obtained
from Merck (Darmstadt, Germany). HPLC grade CH2Cl2 and acetoni-
trile were obtained from Fischer Scientific (Loughborough, United
Kingdom). Solid phase peptide synthesis was performed on a PTI
Tribute-UV peptide synthesizer. Lyophilizations were performed on
a Christ Alpha 2–4 LDplus apparatus. Reactions were carried out at
ambient temperature unless stated otherwise. Solvents were evapo-
rated under reduced pressure at 40C. Reactions in solution were
monitored by TLC analysis and Rf-values were determined on Merck
pre-coated silica gel 60 F-254 (0.25 mm) plates. Spots were visual-
ized by UV-light and permanganate stain. Column chromatography
was performed on Siliaflash P60 (40-63 μm) from Silicycle (Canada)
or on a Biotage Isolera One purification system using prepacked sil-
ica (KP-SIL) Biotage SNAP cartridges. 1H NMR data was acquired
on a Bruker 400 MHz spectrometer in CDCl3 as solvent. Chemical
shifts (δ) are reported in parts per million (ppm) relative to
trimethylsilane (TMS, 0.00 ppm). Analytical high-pressure liquid
chromatography (HPLC) was carried out on a Shimadzu instrument
comprising a communication module (CBM-20A), autosampler (SIL-
20HT), pump modules (LC-20AT), UV/Vis detector (SPD-20A) and
system controller (Labsolutions V5.54 SP), with a Phenomenex Gem-
ini C18 column (110 Å, 5 μm, 250 × 4.60 mm) or Dr. Maisch
Reprosil Gold 200 C18 (5 μm, 250 × 4.60 mm). UV measurements
were recorded at 214 and 254 nm, using a standard protocol: 100%
buffer A (acetonitrile/H2O 5:95 with 0.1% TFA) for 2 min followed
by a linear gradient of buffer B (acetonitrile/H2O 95:5 with 0.1%
TFA) into buffer A (0–100% or 0–50%) over 30 min at a flow rate
of 1.0 mLmin−1. Liquid chromatography mass spectrometry (LCMS)
was carried out on a Thermo Scientific LCQ Fleet quadrupole mass
spectrometer with a Dionex Ultimate 3000 LC using a Dr. Maisch
Reprosil Gold 120 C18 column (110 Å, 3 μm, 150 × 4.0 mm) and
the same linear gradients of buffer B into buffer A, flowrate and
buffers as described for the analytical HPLC. Purification of the pep-
tidic compounds was performed on an Agilent Technologies 1260
infinity preparative system using both UV and ELSD detectors with
a Dr. Maisch Reprosil Gold 200 C18 (10 μm, 250 × 20 mm). Auto-
matic collection of fractions was based on the UV measurements at
214 nm, using customized protocols using the same buffers as
described for the analytical HPLC.
2.2 | Hinge, linker and peptide synthesis
2.2.1 | 2,4,6-tris (bromomethyl)-s-triazine (TBMT)
and 1,10,100-(1,3,5-triazinane-1,3,5-triyl)tris
(2-bromoethanone) (TATB)
These syntheses were carried out as described by van de Langemheen
et al.16
F IGURE 2 Thiol-maleimide
conjugation of epitope mimics forming a
plate-surface with uniformly oriented
peptides used for ELISA to evaluate
epitope mimicry
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2.2.2 | 1-(azidomethyl)-3,5-bis (bromomethyl)-s-
triazine 1, azido triazinane-tris(2-bromoethanone)
2, and 1-(azidomethyl)-3,5-bis (bromomethyl)benzene
3
These syntheses were carried out as described by van de Langemheen
et al.16
2.2.3 | Cyclization linker 4
These syntheses were carried out as described by van de Meuleman
et al.17
2.2.4 | Tetraethylene glycol mono-trityl thioether
5
These syntheses were carried out as described earlier by Meuleman
et al.17
2.2.5 | Alkyne functionalized tetraethylene glycol
monotrityl thioether 6
All steps were performed under N2 atmosphere. Tetraethylene glycol
monotrityl thioether 5 (2.42 g, 5.3 mmol; 1.0 equiv.) was dissolved in
dry THF (150 ml). The resulting solution was cooled to 0C using an
ice bath, followed by addition of sodium hydride (60% dispersion in
mineral oil, 0.32 g, 8.0 mmol; 1.5 equiv.). The resulting reaction mix-
ture was stirred for 1 hour at 0C. After which, propargyl bromide
(80 wt.% in toluene, 770 μl, 6.9 mmol; 1.3 equiv.) was added to the
reaction mixture. The ice bath was removed and the reaction mixture
was stirred for 1 day at RT, after which the reaction had not achieved
complete conversion as yet according to TLC (EtOAc). Nevertheless,
solvent was removed in vacuo and the residue was taken up in CH2Cl2
(100 ml). The resulting sodium bromide precipitate was filtered off
over Celite and the filtrate was concentrated in vacuo. Purification by
automated flash column chromatography using a linear gradient of
EtOAc in petroleum ether 40–60C (0–50% over 20 column volumes)
afforded pure alkyne modified tetraethylene glycol monotrityl
thioether 6 (1.50 g, 3.0 mmol; 58%). Rf = 0.86 (100% EtOAc);
tR = 32.7 min;
1H-NMR (400 MHz, CDCl3): δ = 7.41 (m, 6H, trityl o-H),
7.27 (m, 6H, trityl m-H), 7.21 (m, 3H, p-H), 4.19 (d, 3JHH = 2.3 Hz, 2H,
CH2CCH), 3.67 (m, 4H, CH2), 3.62 (m, 4H, CH2), 3.56 (m, 2H,
CH2CH2O-Alkyne), 3.45 (m, 2H, CH2CH2O-Alkyne), 3.30 (t,
3JHH = 6.9 Hz, 2H, SCH2CH2), 2.43 (t,
3JHH = 6.9 Hz, 2H, SCH2), 2.40
(t, 3JHH = 2.3 Hz, 1H, CCH);
13C-NMR (101 MHz, CDCl3): δ = 144.8
(Ar-C), 129.6 (trityl o-C), 127.9 (trityl m-C), 126.6 (trityl p-C), 79.7
(CCH), 74.5 (CCH), 70.6 (CH2), 70.5 (CH2), 70.4 (CH2CH2O-Alkyne),
70.2 (CH2CH2O-Alkyne), 69.6 (SCH2CH2), 69.1 (CH2), 66.6 (CS), 58.4
(CH2CCH), 31.7 (SCH2); HRMS: m/z calc. For C30H34O4S: 513.2076
[M + Na]+1; found: 513.2062.
2.2.6 | General method for automated peptide
synthesis
Peptides were synthesized on a PTI Tribute-UV peptide synthesizer.
Tentagel S RAM resin (1.0 g, 0.25 mmol, 1.0 equiv or 400 mg, 0.1 mmol,
1.0 equiv) was allowed to swell in DMF (3 x 10 min). De-protection of
the Fmoc group was achieved by treatment of the resin with 20%
piperidine in DMF using the RV_top_UV_Xtend protocol from the
Tribute-UV peptide synthesizer followed by a DMF washing step (5 x
30 sec). Fmoc-protected amino acids were coupled using HCTU (on the
0.1 mmol scale 5 equiv. were used and on the 0.25 mmol scale 4 equiv.
were used) and DiPEA (on the 0.1 mmol scale 10 equiv. were used and
on the 0.25 mmol scale 8 equiv. were used) in DMF, as a coupling
reagent, with 2 min pre-activation. The coupling time was 10 min when
the peptide was synthesized on a 0.1 mmol scale and 20 min when the
0.25 mmol scale was conducted. After every coupling the resin was
washed with DMF (6 x 30 sec), followed by a capping step for
10 minutes using capping solution (on both the 0.1 mmol scale and the
0.25 mmol scale 15 equiv. acetic anhydride and 3 equiv. DiPEA were
used). After coupling of the last amino acid, the Fmoc group was
cleaved using the standard de-protection conditions (described above)
and the resulting free N-terminus was maintained (peptide 7) or acety-
lated (peptides 8–10) by treating the resin bounded peptide with cap-
ping solution (on both the 0.1 mmol scale and the 0.25 mmol scale
15 equiv. acetic anhydride and 3 equiv. DiPEA were used) for
10 minutes. After the last step the resin was washed with DMF (5 x
30 sec) and dried over a nitrogen flow for 10 min.
Cleavage and de-protection was achieved by treatment of the resin
with TFA/H2O/TIS/EDT (15 mL for the 0.25 mmol scale and 5 mL for
the 0.1 mmol scale, 90:5:2.5:2.5, v/v/v/v) for 3 h at rt. The peptide was
then precipitated in Et2O (90 mL for the 0.25 mmol scale and 45 mL for
the 0.1 mmol scale), centrifuged (4500 rpm; 5 min), the supernatant
decanted and the pellet washed 3 times with Et2O (90 mL for the
0.25 mmol scale and 45 mL for the 0.1 mmol scale). The resulting pellet
was re-dissolved in tBuOH:H2O (1:1, v/v) and lyophilized.
2.2.7 | Peptide 7
This peptide was synthesized as described above by solid phase syn-
thesis on a 0.25 mmol scale, which afforded crude peptide (384.0 mg).
The crude peptide was used in the cyclization by alkylation step.
tR = 16.5 min; LRMS: m/z calculated for C79H127N27O22S2: 935.96
½[M + 2H]2+; found: 936.50.
2.2.8 | Peptide 8
This peptide was synthesized as described above by solid phase syn-
thesis on a 0.25 mmol scale, which afforded crude peptide (401.0 mg).
The crude peptide was used in the cyclization by alkylation step.
tR = 20.8 min; LRMS: m/z calculated for C89H117N21O19S2: 924.92
½[M + 2H]2+; found: 925.42 (13C [+1]).
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2.2.9 | Peptide 9
This peptide was synthesized as described above by solid phase syn-
thesis on a 0.25 mmol scale, which afforded crude peptide (354.2 mg).
The crude peptide was used in the cyclization by alkylation step.
tR = 18.8 min; LRMS: m/z calculated for C81H119N21O28S2: 949.91
½[M + 2H]2+; found: 950.17 (13C [+1]).
2.2.10 | Peptide 10
This peptide was synthesized as described above by solid phase syn-
thesis on a 0.25 mmol scale, which afforded crude peptide (400.4 mg).
The crude peptide was used in the cyclization by alkylation step.
tR = 19.1 min; LRMS: m/z calculated for C90H119N21O19S2: 931.93
½[M + 2H]2+; found: 932.33 (13C [+1]).
2.2.11 | General method for peptide cyclization
Crude peptide (1.0 equiv.) was dissolved in DMF (30 ml), followed
by addition of cyclization hinge (1.1–1.5 equiv.) in DMF (1 mL). Sub-
sequently, an aqueous solution of NH4HCO3 (20 mM, pH 7.2<7.4;
10 mL) or H2O (10 mL) was added dropwise to the reaction mix-
ture. The resulting reaction mixture consisted of <1mM peptide
concentration was stirred for 15 minutes (NH4HCO3) or 1 hour
(H2O) at room temperature, followed by removal of the solvents in
vacuo (60C). The residue was dissolved in tBuOH/H2O (1:1, v/v)
aided by sonication. Lyophilization afforded the crude cyclized
peptides.
2.2.12 | Epitope mimics 34–37
Removal of the Trityl group was performed using TFA:H2O:TIS:EDT
(90:5:2.5:2.5, v/v/v/v) (1 ml) for 15 minutes at room temperature,
affording the free-thiol moiety. Then, the product was precipitated in
Et2O (15 ml) and collected by centrifugation (4500 rpm; 5 min). The
collected precipitate was washed twice using Et2O (15 ml), followed
by centrifugation (4500 rpm; 5 min). After which, the precipitate was
dissolved in tBuOH:H2O (1:1, v/v) and lyophylized, which afforded the
crude epitope mimics. The crude product was dissolved in HPLC
buffer and the resulting solution was clarified by centrifugation
(4500 rpm; 5 min), after which, the compound in the supernatant was
purified by preparative HPLC.
2.2.13 | Cyclic peptide 11
Peptide 7 (47.0 mg, 25.1 μmol; 1.0 equiv.) was treated with
1-(azidomethyl)-3,5-bis (bromomethyl)-s-triazine 1 (12.1 mg,
37.6 μmol; 1.5 equiv.) in DMF/H2O as described above. The obtained
crude product (54.5 mg) was dissolved in 6 mL buffer A and purified
as two batches of 3 mL: 100% buffer A for 5 min followed by a linear
gradient of buffer B into buffer A (0–40%) over 40 min at a flow rate
of 12.5 mLmin−1. Affording cyclic peptide 11 (5.3 mg, 2.6 μmol; 9%
overall yield). tR = 16.7 min; HRMS: calculated m/z for
C85H131N33O22S2: 1015.9872 ½[M + 2H]
+2; found 1015.9878; LRMS:
calculated m/z for C85H131N33O22S2: 1015.99 ½[M + 2H]
2+; found
1016.58 (13C [+1]).
2.2.14 | Cyclic peptide 12
Peptide 7 (46.9 mg, 25.1 μmol; 1.0 equiv.) was treated with azido
triazinane-tris(2-bromoethanone) 2 (15.8 mg, 38.4 μmol; 1.5 equiv.)
in DMF/H2O as described above. The obtained crude product
(66.5 mg) was dissolved in 6 mL buffer A and purified as two
batches of 3 mL: 100% buffer A for 5 min followed by a linear
gradient of buffer B into buffer A (0–40%) over 40 min at a flow
rate of 12.5 mLmin−1. Affording cyclic peptide 12 (6.3 mg,
3.0 μmol; 10% overall yield). tR = 16.6 min; HRMS: calculated m/z
for C88H137N33O25S2: 1061.0031 ½[M + 2H]
2+; found 1061.0027;
LRMS: calculated m/z for C88H137N33O25S2: 1061.00 ½[M + 2H]
2+;
found 1061.50 (13C [+1]).
2.2.15 | Cyclic peptide 13
Peptide 7 (46.8 mg, 25.0 μmol; 1.0 equiv.) was treated with azido di
(bromomethyl)benzene 3 (11.8 mg, 36.9 μmol; 1.5 equiv.) DMF/
NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained crude
product (60.6 mg) was dissolved in 6 mL buffer A and purified as two
batches of 3 mL: 100% buffer A for 5 min followed by a linear gradi-
ent of buffer B into buffer A (0–40%) over 40 min at a flow rate of
12.5 mLmin−1. Affording cyclic peptide 13 (3.7 mg, 1.8 μmol; 6%
overall yield). tR = 17.0 min; HRMS: calculated m/z for
C88H134N30O22S2: 1014.4943 ½[M + 2H]
2+; found 1014.4966; LRMS:
calculated m/z for C88H134N30O22S2: 1014.49 ½[M + 2H]
2+; found
1015.08 (13C [+1]).
2.2.16 | Cyclic peptide 14
Peptide 8 (46.5 mg, 25.1 μmol; 1.0 equiv.) was treated with
1-(azidomethyl)-3,5-bis (bromomethyl)-s-triazine 1 (9.9 mg,
30.7 μmol; 1.2 equiv.) DMF/NH4HCO3 (pH 7.2 < 7.4) as described
above. The obtained crude product (59.1 mg) was dissolved as
batches of 10–15 mg in 1 mL buffer A:B (1:1, v/v) and purified:
100% buffer A for 5 min followed by a linear gradient of buffer B
into buffer A (30–70%) over 40 min at a flow rate of 12.5 mLmin−1.
Affording cyclic peptide 14 (11.6 mg, 5.8 μmol; 20% overall yield).
tR = 21.0 min; HRMS: calculated m/z for C95H121N27O19S2:
1004.9465 ½[M + 2H]2+; found 1004.9470; LRMS: calculated m/z
for C95H121N27O19S2: 1004.95 ½[M + 2H]
2+; found 1005.50 (13C
[+1]).
MEULEMAN ET AL. 5 of 17
2.2.17 | Cyclic peptide 15
Peptide 8 (46.5 mg, 25.1 μmol; 1.0 equiv.) was treated with azido
triazinane-tris(2-bromoethanone) 2 (11.4 mg, 27.6 μmol; 1.1 equiv.)
DMF/NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained
crude product (63.2 mg) was dissolved in 3 mL buffer A:B (1:1, v/v)
and purified: 20% buffer B in buffer A for 5 min followed by a linear
gradient of buffer B into buffer A (20–60%) over 40 min at a flow rate
of 12.5 mLmin−1. Affording cyclic peptide 15 (17.3 mg, 8.0 μmol;
28% overall yield). tR = 20.3 min; HRMS: calculated m/z for
C98H127N27O22S2: 1049.9623 ½[M + 2H]
2+; found 1049.9598; LRMS:
calculated m/z for C98H127N27O22S2: 1049.96 ½[M + 2H]
2+; found
1050.58 (13C [+1]).
2.2.18 | Cyclic peptide 16
Peptide 8 (46.3 mg, 25.0 μmol; 1.0 equiv.) was treated with azido di
(bromomethyl)benzene 3 (9.0 mg, 28.1 μmol; 1.1 equiv.) DMF/
NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained crude
product (57.6 mg) was dissolved as batches of 10–15 mg in 1 mL
buffer A:B (1:1, v/v) and purified: 30% buffer B in buffer A for 5 min
followed by a linear gradient of buffer B into buffer A (30–70%) over
80 min at a flow rate of 12.5 mLmin−1. Affording cyclic peptide 16
(7.7 mg, 3.8 μmol; 13% overall yield). tR = 21.7 min; HRMS: calculated
m/z for C98H124N24O19S2: 1003.4536 ½[M + 2H]
2+; found
1003.4567; LRMS: calculated m/z for C98H124N24O19S2: 1003.45
½[M + 2H]+2; found 1004.08 (13C [+1]).
2.2.19 | Cyclic peptide 17
Peptide 9 (47.9 mg, 25.2 μmol; 1.0 equiv.) was treated with
1-(azidomethyl)-3,5-bis (bromomethyl)-s-triazine 1 (10.7 mg,
33.3 μmol; 1.3 equiv.) DMF/NH4HCO3 (pH 7.2 < 7.4) as described
above. The obtained crude product (57.6 mg) was suspended in 3 mL
buffer A:B (1:1, v/v) and centrifuged (4500 rpm; 5 min), which resulted
in a pellet of un-dissolved crude (29.8 mg; after lyophilization). The
supernatant was purified: 20% buffer B in buffer A for 5 min followed
by a linear gradient of buffer B into buffer A (20–60%) over 40 min at
a flow rate of 12.5 mLmin−1. Affording cyclic peptide 17 (6.3 mg,
3.1 μmol; 18% overall yield). tR = 18.8 min; HRMS: calculated m/z for
C87H123N27O28S2: 1029.9314 ½[M + 2H]
2+; found 1029.9345; LRMS:
calculated m/z for C87H123N27O28S2: 1029.93 ½[M + 2H]
2+; found
1030.25 (13C [+1]).
2.2.20 | Cyclic peptide 18
Peptide 9 (47.9 mg, 25.2 μmol; 1.0 equiv.) was treated with azido
triazinane-tris(2-bromoethanone) 2 (11.3 mg, 27.5 μmol; 1.1 equiv.)
DMF/NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained crude
product (65.3 mg) was suspended in 3 mL buffer A:B (1:1, v/v) and
centrifuged (4500 rpm; 5 min), which resulted in a pellet of un-dissolved
crude (16.8 mg; after lyophilization). The supernatant was purified: 20%
buffer B in buffer A for 5 min followed by a linear gradient of buffer B
into buffer A (20–60%) over 40 min at a flow rate of 12.5 mLmin−1.
Affording cyclic peptide 18 (14.1 mg, 6.6 μmol; 26% overall yield).
tR = 18.8 min; HRMS: calculated m/z for C90H129N27O31S2: 1074.9473
½[M + 2H]2+; found 1074.9444; LRMS: calculated m/z for
C90H129N27O31S2: 1074.95 ½[M + 2H]
2+; found 1075.42 (13C [+1]).
2.2.21 | Cyclic peptide 19
Peptide 9 (47.9 mg, 25.2 μmol; 1.0 equiv.) was treated with azido di
(bromomethyl)benzene 3 (8.9 mg, 27.9 μmol; 1.1 equiv.) DMF/
NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained crude
product (56.3 mg) was suspended in 3 mL buffer A:B (1:1, v/v) and
centrifuged (4500 rpm; 5 min), which resulted in a pellet of un-
dissolved crude (39.5 mg; after lyophilization). The supernatant was
purified: 20% buffer B in buffer A for 5 min followed by a linear gradi-
ent of buffer B into buffer A (20–60%) over 40 min at a flow rate of
12.5 mLmin−1. Affording cyclic peptide 19 (1.4 mg, 0.7 μmol; 7%
overall yield). tR = 19.6 min; HRMS: calculated m/z for
C90H126N24O28S2: 1028.4386 ½[M + 2H]
2+; found 1028.4374; LRMS:
calculated m/z for C90H126N24O28S2: 1028.44 ½[M + 2H]
2+; found
1028.92 (13C [+1]).
2.2.22 | Cyclic peptide 20
Peptide 10 (46.6 mg, 25.0 μmol; 1.0 equiv.) was treated with
1-(azidomethyl)-3,5-bis (bromomethyl)-s-triazine 1 (8.9 mg, 27.6 μmol;
1.1 equiv.) DMF/NH4HCO3 (pH 7.2 < 7.4) as described above. The
obtained crude product (59.7 mg) was dissolved in 3 mL buffer A:B
(1:1, v/v) and purified: 20% buffer B in buffer A for 5 min followed by
a linear gradient of buffer B into buffer A (20–60%) over 40 min at a
flow rate of 12.5 mLmin−1. Affording cyclic peptide 20 (12.8 mg,
6.3 μmol; 22% overall yield). tR = 20.9 min; HRMS: calculated m/z for
C96H123N27O19S2: 1011.9543 ½[M + 2H]
2+; found 1011.9544; LRMS:
calculated m/z for C96H123N27O19S2: 1011.95 ½[M + 2H]
2+; found
1012.58 (13C [+1]).
2.2.23 | Cyclic peptide 21
Peptide 10 (46.4 mg, 24.9 μmol; 1.0 equiv.) was treated with azido
triazinane-tris(2-bromoethanone) 2 (11.5 mg, 27.9 μmol; 1.1 equiv.)
DMF/NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained
crude product (61.4 mg) was dissolved in 3 mL buffer A:B (1:1, v/v) and
purified: 20% buffer B in buffer A for 5 min followed by a linear gradi-
ent of buffer B into buffer A (20–60%) over 40 min at a flow rate of
12.5 mLmin−1. Affording cyclic peptide 21 (15.0 mg, 7.1 μmol; 25%
overall yield). tR = 20.5 min; HRMS: calculated m/z for
C99H129N27O22S2: 1056.9702 ½[M + 2H]
2+; found 1056.9688; LRMS:
calculated m/z for C99H129N27O22S2: 1056.97 ½[M + 2H]
2+; found
1057.58 (13C [+1]).
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2.2.24 | Cyclic peptide 22
Peptide 10 (46.5 mg, 25.0 μmol; 1.0 equiv.) was treated with azido di
(bromomethyl)benzene 3 (8.8 mg, 27.6 μmol; 1.1 equiv.) DMF/
NH4HCO3 (pH 7.2 < 7.4) as described above. The obtained crude
product (59.2 mg) was dissolved in 3 mL buffer A:B (1:1, v/v) and puri-
fied: 20% buffer B in buffer A for 5 min followed by a linear gradient
of buffer B into buffer A (20–60%) over 40 min at a flow rateof
12.5 mLmin−1. Affording cyclic peptide 22 (11.7 mg, 5.8 μmol; 20%
overall yield). tR = 21.8 min; HRMS: calculated m/z for
C99H126N24O19S2: 1010.4614 ½[M + 2H]
2+; found 1010.4581; LRMS:
calculated m/z for C99H126N24O19S2: 1010.46 ½[M + 2H]
2+; found
1011.08 (13C [+1]).
2.2.25 | General method for CuAAC of cyclized
peptides to propargyl linker 6
Hinge cyclized peptide (1.0 equiv.), linker 3 (1.1 equiv.), and TBTA (0.5
equiv.) were dissolved separately in DMF (100 μl). The separate
reagents were then combined. After which, CuSO4•5H2O (1.8 equiv.)
was dissolved in H2O (100 μl), and sodium L-ascorbate (10.0 equiv.)
and aminoguanidine•HCl (11.0 equiv, addition of this was omitted in
the preparation of epitope mimics 26–28, as no arginine residues are
present in their peptide sequence) were each dissolved separately in
H2O (50 μl). A premix was prepared by adding the sodium L-ascorbate
(50 μl) solution to the CuSO4•5H2O (100 μl) solution, followed by
immediate addition of the aminoguanidine•HCl (50 μl) solution. Then,
the premix (200 μl) was added to the reaction mixture, which was
stirred for 15 minutes at room temperature under constant N2 flow.
Analysis by analytical HPLC indicated completion of the reaction after
15 minutes, followed by addition of HPLC buffers A:B (1:1, v/v)
(500 μl). The solution was centrifuged (12.000 rpm; 5 min) and the
compound in the supernatant was purified by preparative HPLC: 50%
buffer A for 5 min followed by linear gradient of buffer B into buffer
A (50–100%) over 10 min at a flow rate of 12.5 mLmin−1 using the
same buffers as described for the analytical HPLC. Fractions con-
taining pure product were identified by analytical HPLC and were
pooled and lyophilized, affording pure Trityl-protected product as a
fluffy white powder.
Removal of the Trityl group was performed using TFA:H2O:TIS:EDT
(90:5:2.5:2.5, v/v/v/v) (1 ml) for 15 minutes at room temperature,
affording the free-thiol moiety. Then, the product was precipitated in
Et2O (15 ml) and collected by centrifugation (4500 rpm; 5 min). The col-
lected precipitate was washed twice using Et2O (15 ml), followed by cen-
trifugation (4500 rpm; 5 min). After which, the precipitate was dissolved
in tBuOH:H2O (1:1, v/v) and lyophylized, affording the pure product.
2.2.26 | Epitope mimic 23
Cyclic peptide 11 (5.3 mg, 2.6 μmol) and linker 6 (5.0 mg, 10.2 μmol;
dissolved in 355 μl DMF of which 100 μl was used) was subjected to
the above described CuAAC with CuSO4•5H2O (1.9 mg, 7.6 μmol;
dissolved in 162 μl H2O of which 100 μl was used), L-ascorbate
(16.0 mg, 80.8 μmol; dissolved in 162 μl H2O of which 50 μl was
used), TBTA (1.1 mg, 2.1 μmol; dissolved in 179 μl DMF of which
100 μl was used), aminoguanidine•HCl (5.5 mg, 49.8 μmol; dissolved
in 87 μl of which 50 μl was used). Purification and subsequent
deprotection, afforded epitope mimic 23 (0.9 mg, 0.4 μmol, 15%).
tR = 17.4 min; HRMS: calculated m/z for C96H151N33O26S3: 760.3635
1/3[M + 3H]+3; found 760.3664; LRMS: calculated m/z for
C96H151N33O26S3: 1140.04 ½[M + 2H]
2+/760.36 1/3[M + 3H]+3;
found 1140.50/760.67 (13C [+1]).
2.2.27 | Epitope mimic 24
Cyclic peptide 12 (3.7 mg, 1.7 μmol) and linker 6 (4.1 mg, 8.4 μmol;
dissolved in 440 μl DMF of which 100 μl was used) was subjected to
the above described CuAAC with CuSO4•5H2O (4.7 mg, 18.8 μmol;
dissolved in 605 μl H2O of which 100 μl was used), L-ascorbate
(12.7 mg, 64.1 μmol; dissolved in 188 μl H2O of which 50 μl was
used), TBTA (1.7 mg, 3.2 μmol; dissolved in 400 μl DMF of which
100 μl was used), aminoguanidine•HCl (6.5 mg, 58.8 μmol; dissolved
in 157 μl of which 50 μl was used). Purification and subsequent
deprotection, afforded epitope mimic 24 (1.3 mg, 0.6 μmol, 35%).
tR = 17.3 min; HRMS: calculated m/z for C99H157N33O29S3: 790.3740
1/3[M + 3H]+3; found 790.3769; LRMS: calculated m/z for
C99H157N33O29S3: 1185.06 ½[M + 2H]
2+/790.37 1/3[M + 3H]+3;
found 1185.50/790.67 (13C [+1]).
2.2.28 | Epitope mimic 25
Cyclic peptide 13 (3.7 mg, 1.8 μmol) and linker 6 (4.6 mg, 9.4 μmol;
dissolved in 475 μl DMF of which 100 μl was used) was subjected to
the above described CuAAC with CuSO4•5H2O (3.3 mg, 13.2 μmol;
dissolved in 405 μl H2O of which 100 μl was used), L-ascorbate
(9.9 mg, 50.0 μmol; dissolved in 139 μl H2O of which 50 μl was used),
TBTA (0.9 mg, 1.7 μmol; dissolved in 210 μl DMF of which 100 μl was
used), and aminoguanidine•HCl (6.8 mg, 61.5 μmol; dissolved in
155 μl of which 50 μl was used). Purification and subsequent
deprotection, afforded only a trace of epitope mimic 25. tR = 17.5 min;
HRMS: calculated m/z for C99H154N30O26S3: 759.3682 1/3
[M + 3H]+3; found 759.3712; LRMS: calculated m/z for
C99H154N30O26S3: 1138.55 ½[M + 2H]
2+/759.37 1/3[M + 3H]3+;
found 1139.08/759.67 (13C [+1]).
2.2.29 | Epitope mimic 26
Cyclic peptide 14 (2.0 mg, 1.0 μmol) was dissolved in 200 μl of a linker
6 (10.9 mg, 22.2 μmol; dissolved in 4.0 ml DMF) solution. Next, 100 μl
of a TBTA (0.3 mg, 0.6 μmol; dissolved in 125 μl DMF) solution was
added. Then, 100 μl of a CuSO4•5H2O (1.6 mg, 6.4 μmol; dissolved in
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355 μl H2O) solution and 100 μl of a L-ascorbate (3.2 mg, 16.2 μmol;
dissolved in 160 μl H2O) solution were premixed, of which 200 μl was
added to the reaction mixture. After 15 minutes, the reaction was
complete as gauged by analytical HPLC. Purification and subsequent
deprotection, afforded epitope mimic 26 (0.4 mg, 0.2 μmol, 20%).
tR = 21.2 min; HRMS: calculated m/z for C106H141N27O23S3:
1129.0006 ½[M + 2H]2+; found 1129.0049; LRMS: calculated m/z for
C106H141N27O23S3: 1129.00 ½[M + 2H]
2+; found 1129.33 (13C [+1]).
2.2.30 | Epitope mimic 27
Cyclic peptide 15 (2.0 mg, 1.0 μmol) was dissolved in 200 μl DMF,
followed by addition of 200 μl of a linker 6 (5.2 mg, 10.5 μmol;
dissolved in 2.1 ml DMF) solution. Next, 200 μl of a TBTA
(0.3 mg, 0.6 μmol; dissolved in 200 μl DMF) solution was added.
Then, 400 μl of a CuSO4•5H2O (2.9 mg, 11.6 μmol; dissolved in
1.3 ml H2O) solution and 400 μl of a L-ascorbate (6.8 mg,
34.3 μmol; dissolved in 690 μl H2O) solution were premixed, of
which 400 μl was added to the reaction mixture. After 15 minutes,
the reaction was complete as gauged by analytical HPLC. Purifica-
tion and subsequent deprotection, afforded epitope mimic 27
(0.9 mg, 0.4 μmol, 40%). tR = 20.9 min; HRMS: calculated m/z for
C109H147N27O26S3: 1174.0165 ½[M + 2H]
2+; found 1174.0163;
LRMS: calculated m/z for C109H147N27O26S3: 11174.02
½[M + 2H]2+; found 1174.42 (13C [+1]).
2.2.31 | Epitope mimic 28
Cyclic peptide 16 (2.0 mg, 1.0 μmol) was dissolved in 200 μl of a
linker 6 (10.9 mg, 22.2 μmol; dissolved in 4.0 ml DMF) solution.
Next, 100 μl of a TBTA (0.9 mg, 1.7 μmol; dissolved in 375 μl
DMF) solution was added. Then, 400 μl of a CuSO4•5H2O
(4.0 mg, 16.0 μmol; dissolved in 890 μl H2O) solution and 400 μl
of a L-ascorbate (11.7 mg, 59.0 μmol; dissolved in 590 μl H2O)
solution were premixed, of which 200 μl was added to the reaction
mixture. After 15 minutes, the reaction was complete by analytical
HPLC. Purification and subsequent deprotection, afforded only a
trace of epitope mimic 28. tR = 21.5 min; HRMS: calculated m/z
for C109H144N24O23S3: 1127.5077 ½[M + 2H]
2+; found 1127.5071;
LRMS: calculated m/z for C109H144N24O23S3: 1127.51
½[M + 2H]2+; found 1127.92 (13C [+1]).
2.2.32 | Epitope mimic 29
Pure cyclic peptide 17 (3.3 mg, 1.6 μmol) and linker 6 (3.1 mg,
6.3 μmol; dissolved in 262 μl DMF of which 100 μl was used) was
subjected to the above described CuAAC with CuSO4•5H2O
(2.3 mg, 9.2 μmol; dissolved in 320 μl H2O of which 100 μl was
used), L-ascorbate (11.8 mg, 59.6 μmol; dissolved in 185 μl H2O of
which 50 μl was used), TBTA (1.7 mg, 3.2 μmol; dissolved in
440 μl DMF of which 100 μl was used), aminoguanidine•HCl
(9.0 mg, 81.4 μmol; dissolved in 230 μl of which 50 μl was used).
Purification and subsequent deprotection, afforded only a trace of
epitope mimic 29.
2.2.33 | Epitope mimic 30
Cyclic peptide 18 (10.7 mg, 5.0 μmol) and linker 6 (4.1 mg, 8.4 μmol;
dissolved in 112 μl DMF of which 100 μl was used) was subjected to
the above described CuAAC with CuSO4•5H2O (10.2 mg, 40.9 μmol;
dissolved in 455 μl H2O of which 100 μl was used), L-ascorbate
(17.7 mg, 89.3 μmol; dissolved in 89.3 μl H2O of which 50 μl was
used), TBTA (4.9 mg, 9.2 μmol; dissolved in 405 μl DMF of which
100 μl was used), aminoguanidine•HCl (15.8 mg, 143.0 μmol; dis-
solved in 130 μl of which 50 μl was used). Purification and subsequent
deprotection, afforded epitope mimic 30 (1.7 mg, 0.7 μmol, 14%).
tR = 19.2 min; HRMS: calculated m/z for C101H149N27O35S3:
1220.9834 ½[M + 2Na]2+; found 1220.9838 LRMS: calculated m/z for
C101H149N27O35S3: 1199.00 ½[M + 2H]
2+; found 1199.42 (13C [+1]).
2.2.34 | Scrambled mimic 31
Cyclic peptide 20 (6.0 mg, 3.0 μmol) and linker 6 (8.0 mg, 16.3 μmol;
dissolved in 490 μl DMF of which 100 μl was used) was subjected to
the above described CuAAC with CuSO4•5H2O (5.8 mg, 23.2 μmol;
dissolved in 430 μl H2O of which 100 μl was used), L-ascorbate
(15.1 mg, 76.2 μmol; dissolved in 127 μl H2O of which 50 μl was
used), TBTA (1.8 mg, 3.4 μmol; dissolved in 245 μl DMF of which
100 μl was used), aminoguanidine•HCl (7.4 mg, 66.9 μmol; dissolved
in 101 μl of which 50 μl was used). Purification and subsequent
deprotection, afforded epitope mimic 31 (1.0 mg, 0.4 μmol, 13%).
tR = 21.0 min; HRMS: calculated m/z for C107H143N27O23S3:
1136.0084 ½[M + 2H]2+; found 1136.0112; LRMS: calculated m/z for
C107H143N27O23S3: 1136.01 ½[M + 2H]
2+/757.67 1/3[M + 3H]3+;
found 1136.50/758.00 (13C [+1]).
2.2.35 | Scrambled mimic 32
Cyclic peptide 21 (7.0 mg, 3.3 μmol; dissolved in 200 μl) and linker
6 (7.8 mg, 15.9 μmol; dissolved in 640 μl DMF of which 200 μl was
used) was subjected to the above described CuAAC with CuSO4•5H2O
(7.1 mg, 28.4 μmol; dissolved in 955 μl H2O of which 200 μl was used),
L-ascorbate (17.6 mg, 88.8 μmol; dissolved in 270 μl H2O of which
100 μl was used), TBTA (1.8 mg, 3.4 μmol; dissolved in 410 μl DMF of
which 200 μl was used), aminoguanidine•HCl (10.9 mg, 98.6 μmol; dis-
solved in 150 μl of which 100 μl was used). Purification and subsequent
deprotection, afforded epitope mimic 32 (3.1 mg, 1.3 μmol, 39%).
tR = 20.9 min; HRMS: calculated m/z for C110H149N27O26S3:
1181.0243 ½[M + 2H]2+; found 1181.0253; LRMS: calculated m/z for
C110H149N27O26S3: 1181.02 ½[M + 2H]
2+/787.68 1/3[M + 3H]3+;
found 1181.58/788.17 (13C [+1]).
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2.2.36 | Scrambled mimic 33
Cyclic peptide 22 (4.1 mg, 2.0 μmol) and linker 6 (7.4 mg, 15.1 μmol;
dissolved in 685 μl DMF of which 100 μl was used) was subjected to
the above described CuAAC with CuSO4•5H2O (3.3 mg, 13.2 μmol;
dissolved in 365 μl H2O of which 100 μl was used), L-ascorbate
(11.6 mg, 58.6 μmol; dissolved in 147 μl H2O of which 50 μl was
used), TBTA (1.3 mg, 2.4 μmol; dissolved in 265 μl DMF of which
100 μl was used), aminoguanidine•HCl (8.2 mg, 74.2 μmol; dissolved
in 168 μl of which 50 μl was used). Purification and subsequent
deprotection, afforded only a trace of epitope mimic 33. tR = 21.3 min;
HRMS: calculated m/z for C110H146N24O23S3: 1134.5156 ½[M + 2H]
2
+; found 1134.5160; LRMS: calculated m/z for C110H146N24O23S3:
1134.52 ½[M + 2H]2+/756.68 1/3[M + 3H]3+; found 1135.00/756.92
(13C [+1]).
2.2.37 | Epitope mimic 34
Crude peptide 7 (38.2 mg, 20.4 μmol, 1.1 equiv.) was treated with our
previously developed cyclization linker 43 (22.3 mg, 30.6 μmol; 1.5
equiv.) as described above in the general method for peptide cyclization.
The obtained crude product (34.0 mg) was suspended in 4 mL buffer
A and centrifuged (4500 rpm; 5 min), which resulted in a pellet of un-
dissolved crude (9.5 mg; after lyophilization). The supernatant was
purified in two batches of 2 mL: 0% buffer A for 5 min followed by a
linear gradient of buffer B into buffer A (0–40%) over 40 min at a flow
rate of 12.5 mLmin−1. Affording, epitope mimic 34 (1.7 mg, 0.8 μmol;
4% overall yield). tR = 17.5 min; HRMS: calculated m/z for
C96H151N27O26S3: 1098.0321 ½[M + 2H]
2+; found 1098.0355; LRMS:
calculated m/z for C96H151N27O26S3: 1098.03 ½[M + 2H]
2+/732.36
1/3[M + 3H]3+; found 1098.50/732.50 (13C [+1]).
2.2.38 | Epitope mimic 35
Crude peptide 8 (46.2 mg, 25.0 μmol; 1.0 equiv.) was treated with our
previously developed cyclization linker 43 (27.3 mg, 37.5 μmol; 1.5
equiv.) as described above in the general method for peptide cyclization.
The obtained crude product (53.9 mg) was dissolved as three batches
of 10–20 mg in 3 mL buffer A:B (1:1, v/v) and purified: 100% buffer A
for 5 min followed by a linear gradient of buffer B into buffer A
(0–50%) over 60 min at a flow rate of 12.5 mLmin−1. Affording epi-
tope mimic 35 (9.7 mg, 4.5 μmol; 15% overall yield). tR = 22.3 min;
HRMS: calculated m/z for C106H141N21O23S3: 1086.9914 ½[M + 2H]
2
+; found 1086.9949; LRMS: calculated m/z for C106H141N21O23S3:
1086.99 ½[M + 2H]2+; found 1087.25 (13C [+1]).
2.2.39 | Epitope mimic 36
Crude peptide 9 (48.8 mg, 25.7 μmol; 1.0 equiv.) was treated with our
previously developed cyclization linker 43 (28.0 mg, 38.4 μmol; 1.5
equiv.) as described above in the general method for peptide cyclization.
The obtained crude product (56.6 mg) was suspended in 6 mL buffer
A:B (1:1, v/v) and centrifuged (4500 rpm; 5 min), which resulted in a
pellet of un-dissolved crude (19.4 mg; after lyophilization). The super-
natant was purified: 20% buffer B in buffer A for 5 min followed by a
linear gradient of buffer B into buffer A (20–60%) over 40 min at a
flow rate of 12.5 mLmin−1. Affording epitope mimic 36 (0.4 mg,
0.2 μmol; 1% overall yield). tR = 20.1 min; HRMS: calculated m/z for
C98H143N21O32S3: 1109.9607 ½[M-2H]
−2; found 1109.9435; LRMS:
calculated m/z for C98H143N21O32S3: 1111.98 ½[M + 2H]
2+; found
1112.33 (13C [+1]).
2.2.40 | Scrambled mimic 37
Crude cyclic precursor 10 (47.5 mg, 25.5 μmol; 1.0 equiv.) was
treated with our previously developed cyclization linker 43
(20.9 mg, 28.7 μmol; 1.1 equiv.) as described above in the general
method for peptide cyclization. The obtained crude product
(52.4 mg) was dissolved in 3 mL buffer A:B (1:1, v/v) and purified:
20% buffer B in buffer A for 5 min followed by a linear gradient
of buffer B into buffer A (20–60%) over 40 min at a flow rate of
12.5 mLmin−1. Affording epitope mimic 37 (10.1 mg, 4.6 μmol;
16% overall yield). tR = 22.0 min; HRMS: calculated m/z for
C107H143N21O23S3: 1093.9992 ½[M + 2H]
2+; found 1093.9997;
LRMS: calculated m/z for C107H143N21O23S3: 1094.00 ½[M + 2H]
2
+; found 1094.58 (13C [+1]).
2.2.41 | Monoclonal antibodies
The Mabs AP3313, HC84.18, and DAO531 used in this work were pre-
viously described.
2.2.42 | Immobilisation method and ELISA
Immobilisation
Pierce® maleimide activated 96-well plates were purchased from
Thermo Scientific. The wells were washed three times with 200 μL
wash buffer (0.1 M Na3PO4, 0.15 M NaCl, 0.05% Tween
®-20
detergent; pH 7.2). Then, the desired epitope mimic (100–500 μg)
was suspended in 1 mL binding buffer (0.1 M Na3PO4, 0.15 M
NaCl, 10mM EDTA; pH 7.2) and further diluted (10–50 fold) to a
concentration of 10 μg/mL. To each well, 200 μL of the epitope
mimic solution was added and incubated overnight at 4C. After
this, the wells were washed three times with 200 μL wash buffer.
For capping unreacted maleimide groups, immediately before use, a
solution of 10 μg/mL N-acetylated cysteine was prepared and
200 μL was added to each of the wells, followed by incubation
of 1–2 hours at room temperature. The wells were washed
three times with 200 μL wash buffer and used or stored dry at
−20C.
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ELISA
The wells were washed three times with 200 μL wash buffer. A
three-fold dilution series of primary anti-HCV E2 antibodies
(AP3313 [10.0–0.0 ng/ml]; HC84.18 [100.0–0.1 ng/ml]; DAO531
[15.0–0.0 ng/ml]) was prepared over 7 steps and 100 μL was
transferred to each well, followed by incubation for 1–2 hours at
room temperature. After this, the wells were washed three times
with PBST, before supplying 100 μL 1:2000 secondary α-mouse
A4416 (Sigma) to each well. Incubation continued for 1–2 hours at
room temperature, followed by washing the wells three times with
PBST. The plates were developed using 100 μL 3, 30, 5, 50
tetramethylbenzidine (TMB) solution per well, obtained from Life
Technologies, and incubating for 25 minutes at room temperature,
after which, further development was stopped using 200 μL 0.5 M
H2SO4 per well. Absorbance at 450 nm was measured on a
Varioskan (Thermoscientific) or PHERAstar FS (BMG Labtech)
instrument. Background signal (no Mab) was subtracted. The data
are represented as a percentage relative to immobilized epitope
mimic 34, 35, and 36 for antibodies AP33, HC84.1, and DAO5,
respectively, with the absorbance of the highest Mab concentration
being set to 100% per individual experiment. Data was collected
from 3 to 6 independent experiments (AP33 [n = 5]; HC84.1
[n = 6]; DAO5 [n = 3]). All experiments were performed in dupli-
cate. Error bars represent the standard deviation.
3 | RESULTS AND DISCUSSION
Thus, in order to improve the water-solubility of the recently developed
cyclic and linear epitope HCV-E2 mimics equipped with a TEG spacer
for binding to a surface using maleimide-thiol conjugation,17 we have
incorporated our more polar cyclization hinges 1 and 2 (Figure 3)16 in
addition to our previously used benzyl-derivative 3.17 Instead of
installing the different cyclization hinges on our previously developed
TEG spacer directly, as was earlier described for the bis-benzyl bromide
hinge 4, we decided to opt for a more modular approach. The peptides
were cyclized onto the hinges first, followed by CuAAC to install the S-
Trityl-TEG linker used for conjugation to a maleimide plate. The
required propargyl S-trityl-TEG linker 6 was easily accessible from the
earlier synthesized S-Trityl-TEG 5 by alkylation (Scheme 1).17
F IGURE 3 1-(azidomethyl)-3,5-bis (bromomethyl)-s-triazine
(DBMT-N3) 1, azido triazinane-tris(2-bromoethanone) (TADB-
N3) 2, and 1-(azidomethyl)-3,5-bis (bromomethyl)benzene
(DBMB-N3) 3
16,17
SCHEME 1 Synthesis of the propargyl moiety containing
PEG-based thiol linker for cu-catalyzed azide-alkyne cyclo-
addition of cyclic peptides
TABLE 1 Overview of synthetic peptide sequence corresponding to epitope I, II, and III of the HCV E2 glycoprotein. Including a scrambled
negative control 10
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Next, the required dicysteine containing peptides were obtained
by solid phase peptide synthesis (Table 1). These peptide sequences
originated from promising antigenic regions located within the HCV-
E2 glycoprotein denoted as epitopes I (I411QLINTNGSWHINR424, 7),
II (G436 WVAGLFYYHKFN448, 8), and III (T528WGENETDVFLLNN541,
9). Epitope I is a flexible broadly neutralizing immunogenic domain
SCHEME 2 Cyclization of precursor peptides 7–10 with azido cyclization hinges DBMT-N3 1, TADB-N3 2, and DBMB-N3 3. The reported
yields are of purified products, after preparative reverse phase HPLC
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recognized by neutralizing antibody (Nab) AP33 (Table 1).7,13,30 Epi-
tope II is a broadly neutralizing immunogenic domain recognized by
Nab HC84.1 (Table 1).8 Particularly, broadly neutralizing antibodies
AP3313 and HC84.18 are of special interest as they have been found
to neutralize HCV pseudo-particles (HCVpp) carrying E2 glycoprotein
of various genotypes, indicating that these are highly conserved epi-
topes in an otherwise rapidly mutating virus. Epitope III is an immuno-
genic domain of interest, as together with epitopes I and II it is
located in the CD81 binding site of the viral E2 glycoprotein.31 A
sequence within epitope III is recognized by non-neutralizing antibody
DAO5 (Table 1),31 which despite being non-neutralizing will still allow
us to validate the conformation of our epitope mimics. In addition, a
scrambled peptide sequence 10 was synthesized based on the epitope
II region as a negative control.
Cyclization of dicysteine peptides with different hinges DBMT-
N3 1, TADB-N3 2, and DBMB-N3 3 (Figure 3) was carried out as
described by Van de Langemheen et al (Scheme 2).16 Precursor pep-
tide and the chosen cyclization hinge were dissolved in DMF,
followed by dropwise addition of NH4HCO3 buffer (20mM; pH 7.2
< 7.4) or H2O. A lower pH was used when lysine-amines and/or
free N-terminal amines were present in the peptide sequence to
improve selectivity towards thioether formation and avoid alkylation
of the amine. H2O was used for cyclic peptides 11 and 12 to pre-
vent a suspension and potential polymerization, with the exception
of cyclic peptide 13 that required NH4HCO3 buffer. The purification
of peptides cyclized on polar hinges DBMT-N3 1 and TADB-N3
2 hinges was significantly improved, which resulted in higher yields
compared to the peptides cyclized with the DBMB-N3 3 hinge
(Scheme 2). Furthermore, HPLC-traces showed shorter retention
times for peptides cyclized with the DBMT-N3 1 and TADB-N3
2 polar hinges, indicating a higher polarity compared to peptides
cyclized with benzylic hinge 3 (Figure 4). Thus, the water solubility
was indeed improved using the polar DBMT-N3 1 and TADB-N3
2 cyclization hinges. The effect of the latter was the most
prominent.
It was possible to gauge the improved aqueous solubility by
assessing the concentration of the peptide cyclized using the different
hinges DMBT-N3 1, TADB-N3 2, and DBMB-N3 3. This was demon-
strated for obtaining cyclic peptides 17, 18, and 19 from the same
batch of (linear) peptide 9. Purification of these compounds resulted
in a suspension that was clarified by centrifugation. The afforded pel-
let was resuspended and lyophilized to assess the amount of crude
product that was present in the supernatant and subsequently puri-
fied. Crude cyclic peptide 18 based on TADB-N3 2 afforded the
highest concentration (16.2 mg/mL) in the supernatant, followed by
the concentration (9.3 mg/mL) of cyclic peptide 17. As expected cyclic
peptide 19 based on DBMB-N3 3 resulted in the lowest concentration
(5.6 mg/mL) in the supernatant. This showed that the aqueous solubil-
ity improved going from DBMB-N3 3, DBMT-N3 1 to TADB-N3 2 used
as linkers. Purification of crude cyclic peptides 11–13 was not investi-
gated in this way, since the resulting suspension was too fine and
could not be clarified by centrifugation or filtration. In addition, crude
cyclic peptides 14–16 and 20–22 were readily soluble in the concen-
trations used for purification and yielded none to negligible insoluble
pellets after centrifugation. Considering the low to modest yields
obtained for the purified cyclic peptides, we did not perform a similar
concentration study for the purified products.
It is important to note that the amino-acid sequence does remain
the more dominant factor with respect to overall aqueous solubility of
the cyclic peptides. In addition, the therapeutic potential of the (cyclic)
peptides is highly dependent on their amino-acid composition and
does not allow for a lot of changes. For example, peptide 7 exhibits a
very poor water solubility despite leaving the N-terminus non-acety-
lated, as well as incorporation of an extra Arginine-residue. This extra
Arginine-residue was only possible because it is present in roughly
50% of the known available sequences of the HCV E2 glycoprotein
and was not part of the epitope sequence.24
CuAAC is a widely used and highly versatile conjugation method
of an azide and alkyne moiety.32 Typically, the reaction can be con-
ducted using moderate quantities of reagents being CuSO4•5H2O
F IGURE 4 Analytical HPLC traces overlay of peptides 7–9 cyclized on DBMT-N3 (1; purple), TADB-N3 (2; pink), and DBMB-N3 (3; black),
cyclization hinges. Column: Dr. Maisch Reprosil gold 200 C18, 5 μm 250 x 4.6 mm; gradient: 0 to 100% buffer B in 30 minutes
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SCHEME 3 Cyclic epitope mimics with different hinges DBMT-N3 (11, 14, 17, 20), TADB-N3 (12, 15, 18, 21), and DBMB-N3 (13, 16, 19, 22)
based on loops I (green), II (red), III (blue), and a scrambled negative control (black). The red crosses indicate the mimics, which were only obtained
in trace amounts. The green tick marks indicate the mimics, which were obtained in satisfactory amounts
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(0.3 equiv.), sodium-L-ascorbate (0.9 equiv.) and TBTA (0.15 equiv.) in
a mixture of DMF and H2O (3:2, v/v).
29 However, these conditions
were found to be slow and unsuitable for using our newly developed
alkyne linker 6. Possibly, this could be ascribed to an interaction of
the thioether moieties with the formed Cu(I)-catalyst. Optimization of
the reaction conditions afforded our desired ‘clicked’ products 23, 24,
26, 27, 30, 31, and 32 within 15 minutes at room temperature using
more equivalents of the reagents CuSO4•5H2O (1.8 equiv.), sodium-
L-ascorbate (10 equiv.) and TBTA (0.5 equiv.) still in a mixture of DMF
and H2O (3:2, v/v) (Scheme 3).
Arginine-dehydroascorbate adduct formation has been reported
as a side-reaction for CuAAC in the presence of arginine-residues.33
F IGURE 6 ELISA comparing
immobilized epitope I mimics
having (a): DBMT 23 and (B):
TADB 24 hinges and immobilized
scrambled negative controls (A):
DBMT 31 and (B): TADB 32.
Including immobilized epitope I
mimic 34 and immobilized
scrambled negative control 37
based on the previously
published benzylic-based linker
417
F IGURE 7 ELISA comparing
immobilized epitope II mimics
having (a): DBMT 26 and (B):
TADB 27 hinges and immobilized
scrambled negative controls (A):
DBMT 31 and (B): TADB 32.
Including immobilized epitope II
mimic 35 and immobilized
scrambled negative control 37
based on the previously
published benzylic-based linker
417
F IGURE 5 Mimics of epitopes I (green), II (red), III (blue),
and scrambled negative control (black) partly based on the
previously reported cyclization linker. Epitope mimics 35 and
37 were described previously17 and epitope mimics 34 and 36
were included here for completeness of the study
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Dehydroascorbate is a by-product formed from ascorbate after reduc-
tion of Cu (II) to the catalytically active Cu(I)-species. Similar
dehydroascorbate adducts were formed here after prolonged reaction
times with the DBMT-N3 1 polar hinge structure. As was
reported, formation of dehydroascorbate adducts could
be prevented/decreased by supplementing aminoguanidine•HCl
(11 equiv.) to the CuAAC reaction mixture.
After CuAAC, epitope mimics containing the trityl-group
protecting the thiol functionality, had to be purified. However, the
presence of this trityl-group decreased the water-solubility of these
epitope mimics considerably, resulting in benzylic-hinge based mimics
25, 28, and 33 to be obtained only in trace amounts (indicated with
red crosses in Scheme 3). Furthermore, the water-solubility of peptide
9 was not sufficiently improved by the DBMT-N3 1 polar hinge and
also only trace amounts of the corresponding epitope mimic 29 (red
cross in Scheme 3) were obtained (Scheme 3). It was therefore omit-
ted from this study.
Recently Kale et al. reported on the influence of variation of the
incorporated hinge on the structural diversity of macrocyclic peptides
during screening.10 As a consequence we were interested in verifying
the use of alternative azide-functionalized cyclization hinges and
study their impact on antibody binding. To investigate whether differ-
ent cyclization hinges support the desired conformation of synthetic
peptides based on promising HCV E2 epitopes for antibody binding
we decided to employ our previously described ELISA screen.17 In
order to compare the obtained results we wanted to include epitope
mimics 34–37 (Figure 5) based on our previously reported cyclization
linker 4 (Figure 3).17 Since these previously studied epitope mimics
had not been obtained by CuAAC and therefore did not contain a tri-
azole moiety, we had wished to include the corresponding epitope
mimics 25, 28, and 33 containing a triazole moiety for comparison of
their bio-activity monitored by ELISA. Nevertheless, we did not
expect a significant influence of the triazole moiety, because of its dis-
tance from the epitope sequence. Unfortunately, any effect of the tri-
azole moiety could not be studied because epitope mimics 25, 28, and
33 were not obtained in sufficient yields (Scheme 3). The inability of
obtaining these epitopes containing the hydrophobic TBMB hinge
underlines the importance of having a hinge with improved solubility
properties thereby providing better access to the said epitopes.
Epitope mimics 23, 24, 26, 27, 30, 34, 35, and 36, as well as the
scrambled negative controls 31, 32, and 37 (Scheme 3 and Figure 5)
were covalently immobilized on Pierce® maleimide activated 96-well
plates by maleimide-thiol conjugation. Subsequently, the resulting
immobilized epitope mimics and scrambled negative controls were
evaluated for antibody binding by ELISA.17
The immobilized epitope I mimics 23, 24, and 34 were evaluated
in the ELISA against Nab AP33 (Figure 6). Immobilized epitope mimic
24 compared excellently to epitope mimic 34 towards binding of anti-
body Nab AP33. In addition, immobilized epitope mimic 23 showed
excellent binding of Nab AP33. However, the immobilized scrambled
loop 31, serving as a negative control, showed some unexpected bind-
ing of Nab AP33 that was not observed for immobilized scrambled
negative controls 32 and 37 (Figure 6). This suggests that the DBMT-
N3 1 polar hinge causes indirect binding to Nab AP33 and would be
unsuitable for developing an epitope I mimic.
Immobilized loop II mimics 26, 27, and 35 were evaluated for
binding of Nab HC84.1 (Figure 7). Both immobilized epitope mimics
26 and 27 showed similar if not slightly better binding towards Nab
HC84.1 compared to immobilized epitope mimic 35. None of the
immobilized scrambled negative controls 31, 32, and 37 showed bind-
ing of this antibody.
Finally, loop III immobilized mimics 30 and 36 were subjected to
an ELISA against Mab DAO5 (Figure 8). No difference in binding of
Mab DAO5 was observed between immobilized epitope mimics 30
F IGURE 8 ELISA comparing immobilized
epitope III mimics having TADB 30 hinge and
immobilized scrambled negative controls 32.
Including immobilized epitope III mimic 36 and
immobilized scrambled negative control 37 based
on the previously published benzylic-based linker
417
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and 36, and no binding of immobilized scrambled negative controls 32
and 37 was observed of this antibody.
4 | CONCLUSIONS
In conclusion, utilizing more polar cyclization hinges did improve
the water-solubility of cyclic peptides. Higher yields were obtained
for peptides cyclized on DBMT-N3 1 and TADB-N3 2 cyclization
hinges compared to both DBMB-N3 3 (Figure 3) and our previously
reported hinge without the presence of a triazole ring (compound
4, Figure 3).17 As a consequence higher concentrations of com-
pound could be dissolved in the buffer system for purification by
preparative HPLC. In addition, analytical HPLC showed shorter
retention times for DBMT-N3 1 and TADB-N3 2, indicating an
increased polarity and likely an improved water-solubility of the
resulting cyclic peptides. The latter was confirmed by a solubility
experiment. Heinis et al. showed that using different cyclization
hinges have a significant influence on the conformation of the
resulting (bi)cyclic peptides.3,4,9,10,27 However, the epitope mimics
reported here did not show any difference with respect to anti-
body binding as indicated by ELISA for the different cyclization
hinges used. This does not in anyway indicate that the different
cyclization hinges do not induce conformational changes, but in
view of the size of rings of the cyclic peptides, this may not be
‘detected’ by the antibody. It is known that the HCV E2 glycopro-
tein is a flexible protein, adopting multiple different conformations,
and this may be reflected in the individual peptide epitopes. This
dynamic nature of the viral protein may be one of the major hur-
dles that hinder the development of a therapeutic vaccine against
HCV.7.30.34 Nevertheless, our epitope mimics significantly benefit
from the use of more polar cyclization hinges, with respect to
water-solubility, facilitating their purification and evaluation without
compromising their ability for antibody binding.
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